ZYNE Fundamental Analysis - ZYNERBA PHARMACEUTICALS INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ZYNE. ZYNE was compared to 193 industry peers in the Pharmaceuticals industry. While ZYNE seems to be doing ok healthwise, there are quite some concerns on its profitability. ZYNE is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

ZYNE had negative earnings in the past year.

ZYNE had a negative operating cash flow in the past year.

ZYNE had negative earnings in each of the past 5 years.

ZYNE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ZYNE's Return On Assets of -92.85% is on the low side compared to the rest of the industry. ZYNE is outperformed by 78.47% of its industry peers.

Looking at the Return On Equity, with a value of -129.50%, ZYNE is doing worse than 67.94% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-92.85%
ROE	-129.5%
ROIC	N/A

ROA(3y)-59.46%

ROA(5y)-55.04%

ROE(3y)-71.26%

ROE(5y)-65.33%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ZYNE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ZYNE has more shares outstanding than it did 1 year ago.

There is no outstanding debt for ZYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -8.88, we must say that ZYNE is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of ZYNE (-8.88) is worse than 74.64% of its industry peers.

There is no outstanding debt for ZYNE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-8.88

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 3.43 indicates that ZYNE has no problem at all paying its short term obligations.

ZYNE has a Current ratio (3.43) which is comparable to the rest of the industry.

A Quick Ratio of 3.43 indicates that ZYNE has no problem at all paying its short term obligations.

ZYNE has a Quick ratio (3.43) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	3.43
Quick Ratio	3.43

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.98% over the past year.

EPS 1Y (TTM)13.98%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%12.5%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 31.48% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-2.82%

EPS Next 2Y10.85%

EPS Next 3Y15.71%

EPS Next 5Y31.48%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ZYNE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ZYNE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ZYNE's earnings are expected to grow with 15.71% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y10.85%

EPS Next 3Y15.71%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ZYNE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ZYNERBA PHARMACEUTICALS INC

NASDAQ:ZYNE (10/10/2023, 8:00:03 PM)

After market: 1.3015 +0 (+0.12%)

1.3

+0.03 (+2.36%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-14 2023-08-14/bmo

Earnings (Next)11-13 2023-11-13/bmo

Inst Owners0.03%

Inst Owner Change0%

Ins Owners2.98%

Ins Owner Change0%

Market Cap70.12M

Analysts48.89

Price Target1.28 (-1.54%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-6.52%

Min EPS beat(2)-8.36%

Max EPS beat(2)-4.68%

EPS beat(4)2

Avg EPS beat(4)1.11%

Min EPS beat(4)-8.36%

Max EPS beat(4)12.85%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-78.36%

EPS NQ rev (1m)0%

EPS NQ rev (3m)145%

EPS NY rev (1m)0%

EPS NY rev (3m)-4.91%

Revenue NQ rev (1m)99900%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.42
P/tB	2.42
EV/EBITDA	N/A

EPS(TTM)-0.8

EYN/A

EPS(NY)-0.64

Fwd EYN/A

FCF(TTM)-0.59

FCFYN/A

OCF(TTM)-0.59

OCFYN/A

SpS0

BVpS0.54

TBVpS0.54

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-92.85%
ROE	-129.5%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-59.46%

ROA(5y)-55.04%

ROE(3y)-71.26%

ROE(5y)-65.33%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	90.34%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.43
Quick Ratio	3.43
Altman-Z	-8.88

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)101.27%

Cap/Depr(5y)138.76%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)13.98%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%12.5%

EPS Next Y-2.82%

EPS Next 2Y10.85%

EPS Next 3Y15.71%

EPS Next 5Y31.48%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-4.49%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-21.8%

EBIT Next 3Y1.94%

EBIT Next 5Y31.42%

FCF growth 1Y9.96%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y10.18%

OCF growth 3YN/A

OCF growth 5YN/A

ZYNERBA PHARMACEUTICALS INC (ZYNE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens